In a significant advancement for hematopoietic stem cell transplantation (HSCT) or also known as bone marrow transplant, the U.S. Food and Drug Administration (FDA) has approved Tregzi (or Orca-T), a novel allogeneic regulatory T cell-based immunotherapy developed by Orca Bio.1 The therapy is designed to improve chronic graft-versus-host disease (cGVHD)-free survival and enhance hematopoietic reconstitution in adults receiving myeloablative transplants for hematologic malignancies.
- In the context of Tregzi and HSCT, T cell therapy refers to the adoptive transfer of specific T cell subsets to regulate the recipient's immune response.2
- Specifically, it focuses on Tregs, specialized CD4+ T cells acting as the "brakes" of the immune system. Their role is to maintain homeostasis by suppressing the activity of effector T cells. In transplantation, their goal is to stop the donor's T cells from attacking the recipient cGVHD while still allowing the patient's immune system to fight off infections and cancer (Graft-versus-Tumor effect).
The Clinical Challenge: The Cost of Tolerance
For decades, the primary hurdle in allogeneic HSCT has been the management of graft-versus-host disease (GVHD). While chemotherapeutic conditioning and intensive immunosuppression (such as tacrolimus and methotrexate) are necessary to prevent the donor's T cells from attacking the recipient's healthy tissues, these treatments often come with severe side effects, including life-threatening infections and impaired immune recovery.3
Tregzi represents a precision-engineered approach to this problem. Rather than relying solely on broad-spectrum drugs to dampen the immune system, Tregzi utilizes a specific subset of cells, regulatory T cells (Tregs), to modulate the immune response selectively.
Mechanism of Action: A Triple-Action Approach
Tregzi is a complex allogeneic product containing three primary components derived from a matched donor. Its efficacy relies on a staged infusion strategy:
- Hematopoietic Stem and Progenitor Cells (HSPCs): These are administered first (Day 0) to establish the "seed" for the patient's new blood system, allowing for the production of new red cells, white cells, and platelets.
- Regulatory T Cells (Tregs): Also infused on Day 0, these cells act as the "peacekeepers." They possess the unique ability to suppress the activation of allo-reactive effector T cells, thereby preventing the systemic inflammation that characterizes acute and chronic GVHD.
- Conventional T Cells (Tcons): Administered on Day 2 or 3, these cells are responsible for providing "graft-versus-tumor" (GVT) and "graft-versus-infection" activity. By spacing the infusion of Tcons, the therapy allows the Tregs a "head start" to establish a tolerogenic environment before the effector cells are introduced.
Clinical Evidence: The Precision-T Trial
Following phase 1 and 2 clinical trials,3,4 the approval was supported by a phase 3 multicenter trial, the Precision-T Study, which compared Tregzi against a standard-of-care (SoC) unmanipulated allograft.5 The results demonstrated a statistically significant improvement in outcomes:
- Graft-versus-Host Disease: The cumulative incidence of moderate-to-severe chronic GVHD at 12 months was significantly lower in the Tregzi group (12.6%) compared to the control group (44.0%).
- Survival: Patients receiving Tregzi showed an overall survival rate of 94% at one year, compared to 83% in the control arm.
- Engraftment: The therapy demonstrated high efficacy in immune recovery, with 100% of treated patients achieving neutrophil recovery within 28 days of infusion.
Safety and Administration
Like all myeloablative transplant therapies, Tregzi is associated with significant adverse reactions, including mucositis, various infections (viral, bacterial, and fungal), and hemorrhage. The prescribing information highlights the need for vigilant monitoring for graft failure, acute GVHD, and potential infusion reactions.
The administration is a precise three-step intravenous process. After a myeloablative regimen, patients receive HSPCs and Tregs on Day 0, followed by Tcons on Day 2 to 3.
Recommended Dosages for Tregzi
Tregzi is administered as three distinct components (infusion bags) intravenously.6 The target doses are based on the patient's weight (viable cells per patient kilogram):
| Component | Target Dose (per kg) |
|---|---|
| Hematopoietic Stem and Progenitor Cells (HSPCs) |
≥ 1.0 x 106 viable cells/kg |
| Regulatory T Cells (Tregs) | 1.3 x 106 to 3.5 x 106 viable cells/kg |
| Tcons | 1.3 x 106 to 6.9 x 106 viable cells/kg |
Competition for Tregzi
Several competing strategies for managing transplant tolerance are in development, including2:
- Next-Generation Nanomedicines: Developing nanoparticles to deliver IL-2 muteins or antigens to stimulate Tregs.
- Chimeric Antigen Receptor (CAR) Tregs: Engineering T cells with specific CARs to target antigens (like HLA-A2 or CD19) to induce tolerance.
- Checkpoint Inhibitors: PD-1 and CTLA-4 inhibitors.
The Future of Transplantation
The approval of Tregzi marks a shift toward "immunological engineering," in other words, moving away from systemic drug-heavy prophylaxis toward cell-based precision medicine.
References
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol. U.S. Food and Drug Administration. FDA News Release. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
- Wardell, C. M.; Boardman, D. A.; Levings, M. K. Harnessing the biology of regulatory T cells to treat disease. Nat. Rev. Drug Discovery 2025, 24 (2), 93-111.
- Meyer, E. H.; Hoeg, R.; Moroz, A.; Xei, B.; Wu, H.-H.; Pawar, R.; Heydari, K.; Miklos, D. B.; Shiraz, P.; Muffly, L. S.; et al. Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. Blood 2020, 136 (Supplement 1), 47-48.
- Meyer, E.; Pavlova, A.; Gandhi, A.; Hoeg, R.; Oliai, C.; Mehta, R.; Srour, S.; McGuirk, J.; Waller, E.; Fernhoff, N.; et al. S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES. Hemasphere 2022, 6 (Suppl).
- Meyer, E. H.; Salhotra, A.; Gandhi, A. P.; Pantin, J.; Patel, S. S.; Hoeg, R. T.; Gomez-Arteaga, A.; Faramand, R.; Tamari, R.; Waller, E. K.; et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood 2026, 147 (11), 1168-1177.
- Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq). Prescribing information. Orca Biosystems, 2026. Accessed July 26, 2026. https://www.fda.gov/vaccines-blood-biologics/tregzi.